| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Dimitrios Papadopoulos | Q84660213 |
| P2093 | author name string | Dimos Dimitrios Mitsikostas | |
| P2860 | cites work | The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey | Q21710682 |
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 | ||
| Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. | Q30930653 | ||
| Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer | Q33625012 | ||
| Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial | Q33628834 | ||
| Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. | Q33777417 | ||
| Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests | Q33806407 | ||
| Cultural differences: implications on drug therapy and global drug development | Q33856132 | ||
| Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain | Q34101542 | ||
| Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
| Epidemiology and treatment of neuropathic pain: the UK primary care perspective | Q34503159 | ||
| Nonspecific medication side effects and the nocebo phenomenon | Q34519096 | ||
| Placebo response in the prophylaxis of migraine: a meta-analysis. | Q34621702 | ||
| Prevalence of chronic pain with neuropathic characteristics in the general population. | Q34691911 | ||
| Pharmacologic management of neuropathic pain: evidence-based recommendations | Q34699259 | ||
| Neuropathic pain: redefinition and a grading system for clinical and research purposes | Q34713765 | ||
| Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans | Q35688093 | ||
| Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls | Q36013751 | ||
| The impact of neuropathic pain on health-related quality of life: review and implications | Q36786290 | ||
| New insights into the placebo and nocebo responses | Q37230629 | ||
| Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy | Q37404805 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| Clinical characteristics and economic costs of patients with painful neuropathic disorders | Q38479016 | ||
| Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial | Q39395734 | ||
| Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial | Q39402248 | ||
| Patient beliefs predict patient functioning: further support for a cognitive-behavioural model of chronic pain | Q40811050 | ||
| Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. | Q42167709 | ||
| Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial | Q44374546 | ||
| Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial | Q44411545 | ||
| Pain and depression in acute traumatic spinal cord injury: origins of chronic problematic pain? | Q44418572 | ||
| Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial | Q44743462 | ||
| Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects | Q45057234 | ||
| Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial | Q45185821 | ||
| Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
| A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain | Q48389097 | ||
| Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial | Q48484274 | ||
| Exacerbation of pain by anxiety is associated with activity in a hippocampal network. | Q48692398 | ||
| Drug-related information generates placebo and nocebo responses that modify the drug response | Q48766469 | ||
| Gender and the nocebo response following conditioning and expectancy | Q51649240 | ||
| Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions | Q58267475 | ||
| The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers | Q71586838 | ||
| The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies | Q72561497 | ||
| Gender differences in regional brain response to visceral pressure in IBS patients | Q74220110 | ||
| Medication side effects in anxious patients: negative placebo responses? | Q74225052 | ||
| Chronic pain in a community-based sample of men with spinal cord injury: Prevalence, severity, and relationship with impairment, disability, handicap, and subjective well-being | Q74660552 | ||
| Comorbidity of headache and depressive disorders | Q77903346 | ||
| The nocebo reaction | Q79032458 | ||
| P433 | issue | 3 | |
| P921 | main subject | meta-analysis | Q815382 |
| nocebo | Q1332954 | ||
| neuropathic pain | Q2798704 | ||
| P304 | page(s) | 436-447 | |
| P577 | publication date | 2011-08-03 | |
| P1433 | published in | Journal of Neurology | Q6295649 |
| P1476 | title | A meta-analytic approach to estimating nocebo effects in neuropathic pain trials | |
| P478 | volume | 259 |
| Q38219326 | Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. |
| Q64963575 | Are Patients With Schizophrenia Spectrum Disorders More Prone to Manifest Nocebo-Like-Effects? A Meta-Analysis of Adverse Events in Placebo Groups of Double-Blind Antipsychotic Trials. |
| Q38259757 | Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies. |
| Q45181057 | Development of the Stanford Expectations of Treatment Scale (SETS): A tool for measuring patient outcome expectancy in clinical trials |
| Q64067737 | Does Sex/Gender Play a Role in Placebo and Nocebo Effects? Conflicting Evidence From Clinical Trials and Experimental Studies |
| Q44391988 | Gender differences in acute and chronic pain conditions. Implications for diagnosis and therapy |
| Q38815321 | Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects |
| Q60681040 | Informing Adults With Back Pain About Placebo Effects: Randomized Controlled Evaluation of a New Website With Potential to Improve Informed Consent in Clinical Research. |
| Q48099493 | Medicine-related beliefs predict attribution of symptoms to a sham medicine: A prospective study. |
| Q44863430 | Minimizing nocebo effect: Pragmatic approach |
| Q34311226 | Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta‐analysis |
| Q50616272 | Nocebo effects and psychotropic drug action |
| Q42376620 | Nocebo effects in clinical studies: hints for pain therapy |
| Q92510498 | Nocebo in Biosimilars and Generics in Neurology: A Systematic Review |
| Q37970944 | Nocebo in Headaches: Implications for Clinical Practice and Trial Design |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q58795531 | Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent |
| Q35387933 | Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review |
| Q38327044 | Placebo and nocebo effects in the neurological practice |
| Q28072351 | Placebo, nocebo, and neuropathic pain |
| Q48289619 | Proton pump inhibitor-related headaches: a nationwide population-based case-crossover study in Taiwan |
| Q59789438 | Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials |
| Q92241541 | The nocebo effect as a source of bias in the assessment of treatment effects |
| Q36719631 | The nocebo effect of drugs |
| Q38055026 | The nocebo effect: a clinicians guide |
| Q47106974 | Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect |
| Q38972857 | Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. |
| Q40880535 | Unravelling nocebo effect: the mediating effect of anxiety between anticipation and pain at wound dressing change |
| Q48199107 | What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain |
Search more.